Clinical First-in-human Dose Escalation Study Evaluating the Safety and Tolerability of Intravenous Administration of a Tetravalent RNA-lipoplex Cancer Vaccine Targeting Four Tumour-associated Antigens in Patients With Advanced Melanoma

Trial Profile

Clinical First-in-human Dose Escalation Study Evaluating the Safety and Tolerability of Intravenous Administration of a Tetravalent RNA-lipoplex Cancer Vaccine Targeting Four Tumour-associated Antigens in Patients With Advanced Melanoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Apr 2017

At a glance

  • Drugs RBL 001/RBL 002/RBL 003/RBL 004 (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; First in man
  • Acronyms Lipo-MERIT
  • Sponsors BioNTech
  • Most Recent Events

    • 05 Apr 2017 Safety and tolerability results in first 15 patients treated as of January 2017 presented at the 108th Annual Meeting of the American Association for Cancer Research
    • 07 Mar 2017 According to a BioNTech media release, interim data from this trial will be presented at the 2017 Annual Meeting of the American Association for Cancer Research (AACR).
    • 07 Jun 2016 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top